Clinical Trials and Commercialization Using CPPs
Publisher
Springer Singapore
Reference73 articles.
1. Bae, D. G., Kim, T. D., Li, G., Yoon, W. H., & Chae, C. B. (2005). Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clinical Cancer Research, 11, 2651–2661. 2. Bates, E., Bode, C., Costa, M., Gibson, C. M., Granger, C., Green, C., et al. (2008). Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation, 117, 886–896. 3. Bennett, G., Harrison, H., Campbell, S., Teufel, D., Langford, G., Watt, A., et al. (2017). Development of BT1718, a Bicycle Drug Conjugate® (BDC) targeting MT1-MMP for treatment of solid tumours. European Journal of Cancer, 69, S21. 4. Betts, C. A., & Wood, M. J. (2013). Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy. Current Pharmaceutical Design, 19, 2948–2962. 5. Bird, G. H., Mazzola, E., Opoku-Nsiah, K., Lammert, M. A., Godes, M., Neuberg, D. S., et al. (2016). Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. Nature Chemical Biology, 12, 845–852.
|
|